Results 271 to 280 of about 336,398 (336)
ARID1A is frequently mutated in both non‐malignant tissues and cancers, but its role in tumor development after exposure to genotoxic carcinogen remains unclear. It is found that aristolochic acid I accelerated liver tumorigenesis in ARID1A‐deficient context by impairing nucleotide excision repair and enhancing carcinogen bioactivation, revealing key ...
Lan Wang +8 more
wiley +1 more source
This study reveals that CAFs‐derived EVs enriched with circTAX1BP1 drive CRLM by promoting VIRMA lactylation and SP1/TGF‐β signaling, creating a positive feedback loop via ITGA11+ myCAFs. Targeting EV‐circTAX1BP1 and TGF‐β disrupts this loop, offering a novel therapeutic strategy for CRLM.
Jia‐nan Tan +12 more
wiley +1 more source
In-depth analysis of the RNA editing landscape in intracranial aneurysms and its potential role in alternative splicing. [PDF]
Wang Y +5 more
europepmc +1 more source
The precise regulation of AP2M1 is essential for normal hematopoiesis. Overexpression of AP2M1 negatively affects the clinical outcomes of AML patients. Upregulation of AP2M1 enhances stemness and chemoresistance in HSPC cells of AML. AP2M1 modulates NOTCH1 expression, enhancing the Notch1 signaling pathway.
Hansong Lee +28 more
wiley +1 more source
Comprehensive analysis of aberrant alternative splicing and RNA binding proteins associated with age-related sensorineural hearing loss. [PDF]
Yu W +10 more
europepmc +1 more source
The maize transposable Ds1 element is alternatively spliced from exon sequences.
Susan R. Wessler
openalex +1 more source
MARCO+ TAMs dominate restrained cytotoxicity of CD8+ CTLs and ICB resistance in RCC. Mechanically, MARCO impairs MHC‐I‐mediated neoantigen cross‐presentation via the SOCS1‐JAK1‐STAT1‐NLRC5 signaling cascade in TAMs. Targeted MARCO treatment boosts macrophage antigen cross‐presentation and empowers CD8+ T cells, thereby potentiating ICB efficacy ...
Jiayuan Chen +14 more
wiley +1 more source
Saikosaponin‑D triggers cancer cell death by targeting the PIM1/c-Myc axis to reprogram oncogenic alternative splicing. [PDF]
Zhang X +10 more
europepmc +1 more source

